DHRS9 and metastatic malignant neoplasm in the lymph nodes: Reduced expression of DHRS9 was significantly correlated with increased lymph node metastasis (p = 0.032), advanced TNM stage (p = 0.021), increased disease recurrence (p = 0.001), and death (p = 0.014).